Spots Global Cancer Trial Database for diffuse large b cell lymphoma
Every month we try and update this database with for diffuse large b cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma | NCT03797170 | Diffuse Large B... | Gut microbiota ... | 18 Years - | University of Bologna | |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Maintenance Hormonal Therapy and DLBCL | NCT06355401 | Diffuse Large B... | Tamoxifen 20mg | 18 Years - 75 Years | Sohag University | |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | NCT03376958 | Relapsed and Re... Diffuse Large B... | Apatinib | 14 Years - 70 Years | Zhengzhou University | |
| Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers | NCT05834426 | Lymphoma, B-Cel... Neoplasms Cancer High-grade B-ce... Diffuse Large B... Non Hodgkin Lym... Metabolomics | Plasma metabolo... | 18 Years - | Sociedad de Lucha Contra el Cáncer del Ecuador | |
| Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | NCT04503538 | Large B-cell Ly... Diffuse Large B... Primary Mediast... High-grade B-ce... Follicular Lymp... | Telemedicine vi... | 18 Years - | Wake Forest University Health Sciences | |
| A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma | NCT03383406 | Diffuse Large B... | Ifosfamide, Eto... | 19 Years - 60 Years | Asan Medical Center | |
| The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT05673447 | Diffuse Large B... | anti-CD19 CAR N... | 18 Years - 70 Years | Changhai Hospital | |
| Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients | NCT03079947 | Diffuse Large B... Peripheral T Ce... | 18 Years - 80 Years | Peking Union Medical College Hospital | ||
| Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma | NCT03719560 | Diffuse Large B... | Methotrexate Cytarabine | 18 Years - | Brown University | |
| Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma | NCT01466868 | Diffuse Large B... | MK2206 | 18 Years - 90 Years | Centre Leon Berard | |
| Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma | NCT03200015 | Diffuse Large B... | Metformin | 18 Years - | Hospital Universitario Dr. Jose E. Gonzalez | |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | NCT04018248 | Diffuse Large B... Follicular Lymp... Chronic Lymphoc... Small Lymphocyt... B Cell Lymphoma Marginal Zone L... Waldenstrom Mac... Peripheral T Ce... | BR101801 (Phase... BR101801 (Phase... | 18 Years - | Boryung Pharmaceutical Co., Ltd | |
| R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients | NCT03364439 | Diffuse Large B... | Treatment plan | 18 Years - 80 Years | Fondazione Italiana Linfomi - ETS | |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. | NCT05645744 | Blastic Plasmac... Chronic Lymphoc... Small Lymphocyt... Waldenstrom's M... Follicular B-ce... B-cell Lymphoma... Mantle Cell Lym... Hairy Cell Leuk... Diffuse Large B... Waldenstrom's M... Mantle Cell Lym... | Prior MB-102 CA... Prior MB-106 CA... | 18 Years - | Mustang Bio | |
| QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma | NCT04052061 | Diffuse Large B... Large-cell Lymp... Lymphoma, B-Cel... Lymphoma | CD19 t-haNK | 18 Years - | ImmunityBio, Inc. | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma | NCT03513601 | Diffuse Large B... | (R)-CHOP regime... (R)-CVP regimen | 70 Years - 85 Years | Zhengzhou University | |
| Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL) | NCT04460248 | Diffuse Large B... | Zanubrutinib, L... | 75 Years - | Ruijin Hospital | |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma | NCT04112238 | Diffuse Large B... Central Nervous... | 18 Years - | Herlev Hospital | ||
| A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients | NCT02772822 | Diffuse Large B... | SCT400 plus CHO... Rituximab plus ... | 18 Years - 70 Years | Sinocelltech Ltd. | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT03719989 | Diffuse Large B... Relapsed Non Ho... Refractory Non-... | azacitidine plu... | 19 Years - 75 Years | Seoul National University Hospital | |
| Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | NCT03995147 | B Cell Lymphoma Lymphoma Lymphoma, B-Cel... Diffuse Large B... High-grade B-ce... | Pembrolizumab R-CHOP Protocol | 18 Years - | University of Chicago | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | NCT05464329 | Diffuse Large B... High-grade B-ce... Transformed B-C... Follicular Lymp... | Mosunetuzumab DHAX ICE | 18 Years - | Washington University School of Medicine | |
| Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies | NCT06227026 | Acute Lymphobla... Diffuse Large B... | Anti-CD19 CAR-T... | 18 Years - | University of Utah | |
| Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL | NCT03949062 | Diffuse Large B... | Ibrutinib Lenalidomide Rituximab | 75 Years - | Ruijin Hospital | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma | NCT05820841 | Large B-cell Ly... Diffuse Large B... | R-miniCHOP + Ac... R-miniCHOP | 61 Years - | Universität des Saarlandes | |
| Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | NCT02767674 | Diffuse Large B... | Rituximab Gemcitabine Oxaliplatin Cyclophosphamid... Epirubicin Inje... Vindesine Prednisone | 70 Years - 90 Years | The First Affiliated Hospital with Nanjing Medical University | |
| RadiothErapy priMIng for CAR-T | NCT04726787 | Diffuse Large B... | Bridging Radiot... | 18 Years - | University College, London | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA) | NCT05746858 | Diffuse Large B... Relapsed Non-Ho... | no intervention... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL) | NCT04237168 | Lymphoma, Large... | IgNGS from circ... | - | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | |
| A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | NCT04594642 | B-cell Non Hodg... Diffuse Large B... High-grade B-ce... Follicular Lymp... | AZD0486 IV | 18 Years - 130 Years | AstraZeneca | |
| Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy | NCT06141772 | Diffuse Large B... | Measure of the ... | 18 Years - | Centre Henri Becquerel | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma | NCT03576443 | Diffuse Large B... | Idelalisib | 19 Years - | Nordic Lymphoma Group | |
| R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma | NCT04214626 | Diffuse Large B... | Rituximab Lenalidomide Cyclophosphamid... Epirubicin Vincristine Prednisone Methotrexate | 18 Years - 70 Years | Henan Cancer Hospital | |
| Genotype-guided Treatment in DLBCL | NCT05351346 | Diffuse Large B... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Orelabrutinib Lenalidomide Decitabine | 18 Years - 80 Years | Ruijin Hospital | |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients | NCT03028103 | Diffuse Large B... Primary Mediast... Mantle Cell Lym... Advanced Solid ... Marginal Zone L... | Tazemetostat Fluconazole Omeprazole Repaglinide | 18 Years - | Ipsen | |
| FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | NCT05934097 | Diffuse Large B... Transformed Ind... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... | FT596 Cyclophosphamid... Doxorubicin Vincristine Prednisone Rituximab Bendamustine | 18 Years - | Fate Therapeutics | |
| Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | NCT05863845 | Diffuse Large B... | Venetoclax Carmustine Cytarabine Etoposide Melphalan Hematopoietic C... | 18 Years - 65 Years | Ruijin Hospital | |
| Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | NCT05749549 | Advanced Cancer Follicular Lymp... Peripheral T Ce... Diffuse Large B... | BR1733 | 18 Years - | Shanghai Blueray Biopharma Co., Ltd. | |
| PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | NCT06290622 | Diffuse Large B... Lymphoma, B-Cel... Lymphoma, Folli... | Retifanlimab, I... | 18 Years - | University of Alabama at Birmingham | |
| Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy | NCT03422523 | Diffuse Large B... Relapsed Diffus... Refractory Diff... | Atezolizumab Rituximab Gemcitabine 100... Oxaliplatin 100... | 16 Years - | University Hospital Southampton NHS Foundation Trust | |
| Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? | NCT06352242 | Diffuse Large B... | Flow cytometry ... Flow cytometry ... | 18 Years - | University Hospital, Montpellier | |
| Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma | NCT05298293 | Diffuse Large B... | ONCOLAXY Follow... | 18 Years - | Weprom | |
| Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance | NCT03311958 | Diffuse Large B... | Nivolumab, IV, ... | 18 Years - | Fox Chase Cancer Center | |
| Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT01282476 | Diffuse Large B... | Panobinostat wi... | 18 Years - | Massachusetts General Hospital | |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | NCT05326243 | Diffuse Large B... Primary Mediast... Large B-cell Ly... Follicular Lymp... Follicular Lymp... | CD19-targeted c... | 14 Years - 70 Years | Pell Bio-Med Technology Co., Ltd. | |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT02623920 | Diffuse Large B... Mediastinal Lar... Grey Zone Lymph... High Grade B Ce... Follicular Lymp... Marginal Zone L... Small Lymphocyt... | Brentuximab Bendamustine Rituximab | 18 Years - | University of Arizona | |
| Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients | NCT01481272 | Diffuse Large B... | Ofatumumab Etoposide Ifosfamid Mesna Cytarabine Methotrexate Leukovorin Granulocyte-Col... | 18 Years - | Polish Lymphoma Research Group | |
| Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | NCT03676504 | Acute Lymphobla... Acute Lymphobla... Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... | CD19.CAR T Cell... Fludarabine Cyclophosphamid... | 3 Years - | University Hospital Heidelberg | |
| Biomarker Guided Treatment in DLBCL | NCT04025593 | Diffuse Large B... | Cyclophosphamid... Rituximab Doxorubicin Vincristine Prednisone Ibrutinib Lenalidomide chidamide decitabine | 18 Years - 80 Years | Ruijin Hospital | |
| Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma | NCT03576443 | Diffuse Large B... | Idelalisib | 19 Years - | Nordic Lymphoma Group | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients | NCT01481272 | Diffuse Large B... | Ofatumumab Etoposide Ifosfamid Mesna Cytarabine Methotrexate Leukovorin Granulocyte-Col... | 18 Years - | Polish Lymphoma Research Group | |
| 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma | NCT03121456 | Diffuse Large B... | 18F-FDG PET SCA... MRI DIFFUSION | 19 Years - | Centre Antoine Lacassagne | |
| A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | NCT03999697 | Diffuse Large B... Follicular Lymp... Primary Cutaneo... Extranodal Marg... Mantle Cell Lym... Plasma Cell Neo... B Cell Lymphoma | Autologous chim... | 3 Years - 70 Years | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial | NCT04500561 | Diffuse Large B... | YY-20394 | 18 Years - 75 Years | Shanghai YingLi Pharmaceutical Co. Ltd. | |
| Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ | NCT02128061 | Diffuse Large B... | Lenalidomide Rituximab | 80 Years - | The Lymphoma Academic Research Organisation | |
| Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma | NCT00169169 | CD20-Positive L... | ACVBP ACE rituximab Autologous stem... | 18 Years - 59 Years | Lymphoma Study Association | |
| Lenalidomide Monotherapy in R/R DLBCL | NCT04150328 | Diffuse Large B... | 18 Years - | MorphoSys AG | ||
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients | NCT03028103 | Diffuse Large B... Primary Mediast... Mantle Cell Lym... Advanced Solid ... Marginal Zone L... | Tazemetostat Fluconazole Omeprazole Repaglinide | 18 Years - | Ipsen | |
| Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells | NCT04911478 | Lymphoma, Folli... Lymphoma, Mantl... Marginal Zone L... Primary Mediast... Diffuse Large B... Lymphoma, Non-H... | ADI-001 | 18 Years - | Adicet Bio, Inc | |
| A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | NCT04104776 | Advanced Solid ... Diffuse Large B... Lymphoma, T-Cel... Mesothelioma, M... Prostatic Neopl... Endometrial Can... Ovarian Clear C... | CPI-0209 | 18 Years - | Constellation Pharmaceuticals | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma | NCT04544059 | Diffuse Large B... | Lenalidomide | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression | NCT06005870 | Diffuse Large B... | Zanubrutinib pl... | 18 Years - 75 Years | Huazhong University of Science and Technology | |
| Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies | NCT01760226 | Diffuse Large B... Post Transplant... Primary Mediast... | DA-EPOCH-R for ... Methotrexate Etoposide Doxorubicin Vincristine Rituximab Cyclophosphamid... Prednisone G-CSF | - 30 Years | Baylor College of Medicine | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy | NCT05725720 | Diffuse Large B... | Gut microbiome ... | 18 Years - | University of Bologna | |
| Cyclophosphamide and Alemtuzumab In Lymphoma | NCT03132584 | Non Hodgkin Lym... High-grade B-ce... Diffuse Large B... | Cyclophosphamid... Alemtuzumab | 18 Years - 75 Years | Dana-Farber Cancer Institute | |
| LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) | NCT00466258 | HIV Infections Diffuse Large B... | R-CHOP Highly active a... Central nervous... Prophylaxis of ... | 18 Years - 70 Years | PETHEMA Foundation | |
| A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) | NCT01238692 | Diffuse Large B... | LBH589 Rituximab | 18 Years - | Jewish General Hospital | |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | NCT05934838 | Follicular Lymp... B-Cell Lymphoma Mantle Cell Lym... Diffuse Large B... | Tazemetostat Pi... | 18 Years - | Weill Medical College of Cornell University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
